Review the management of resectable gastroesophageal adenocarcinoma (GEA)
Describe the use of immunotherapy in GEA and biomarkers predictive of response to PD-1 blockade
Discuss a clinical trial investigating neoadjuvant pembrolizumab in cT1-2N0M0 resectable GEA
1. Discuss the T cell-inflamed and non-T cell-inflamed tumor phenotype as a framework for identifying mechanisms of immunotherapy resistance.
2. Identification of oncogene pathways associated with non-T cell-inflamed tumors and that mediate immune exclusion.
3. Investigate whether tumor-intrinsic hypoxia-inducible factor-1 alpha (HIF1-alpha) activation mediates T cell exclusion from the tumor microenvironment.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation